AU2021101739A4 - Dedicated Light Source and Lamp for Diabetic Retinopathy - Google Patents
Dedicated Light Source and Lamp for Diabetic Retinopathy Download PDFInfo
- Publication number
- AU2021101739A4 AU2021101739A4 AU2021101739A AU2021101739A AU2021101739A4 AU 2021101739 A4 AU2021101739 A4 AU 2021101739A4 AU 2021101739 A AU2021101739 A AU 2021101739A AU 2021101739 A AU2021101739 A AU 2021101739A AU 2021101739 A4 AU2021101739 A4 AU 2021101739A4
- Authority
- AU
- Australia
- Prior art keywords
- far
- green
- led devices
- light source
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010012689 Diabetic retinopathy Diseases 0.000 title claims abstract description 48
- 239000000758 substrate Substances 0.000 claims abstract description 28
- 239000002994 raw material Substances 0.000 claims description 35
- 230000004907 flux Effects 0.000 claims description 17
- 229920001296 polysiloxane Polymers 0.000 claims description 16
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 15
- 239000003292 glue Substances 0.000 claims description 14
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 11
- 238000003837 high-temperature calcination Methods 0.000 claims description 10
- 239000011812 mixed powder Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 238000001354 calcination Methods 0.000 claims description 6
- 229910001632 barium fluoride Inorganic materials 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000007711 solidification Methods 0.000 claims description 5
- 230000008023 solidification Effects 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 229910000422 cerium(IV) oxide Inorganic materials 0.000 claims description 3
- CETPSERCERDGAM-UHFFFAOYSA-N ceric oxide Chemical compound O=[Ce]=O CETPSERCERDGAM-UHFFFAOYSA-N 0.000 claims description 2
- 229910052681 coesite Inorganic materials 0.000 claims description 2
- 229910052906 cristobalite Inorganic materials 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 229910052682 stishovite Inorganic materials 0.000 claims description 2
- 229910052905 tridymite Inorganic materials 0.000 claims description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 1
- 235000019270 ammonium chloride Nutrition 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 31
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 210000002445 nipple Anatomy 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 18
- 238000010586 diagram Methods 0.000 description 16
- 238000001228 spectrum Methods 0.000 description 15
- 230000004044 response Effects 0.000 description 10
- 230000004310 photopic vision Effects 0.000 description 9
- 210000001525 retina Anatomy 0.000 description 8
- 208000017442 Retinal disease Diseases 0.000 description 6
- 206010038923 Retinopathy Diseases 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000002207 retinal effect Effects 0.000 description 6
- 238000009413 insulation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000008447 perception Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 238000000295 emission spectrum Methods 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 2
- 230000004300 dark adaptation Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910017917 NH4 Cl Inorganic materials 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 description 1
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 1
- 206010047050 Vascular anomaly Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006677 mitochondrial metabolism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/067—Radiation therapy using light using laser light
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F21—LIGHTING
- F21V—FUNCTIONAL FEATURES OR DETAILS OF LIGHTING DEVICES OR SYSTEMS THEREOF; STRUCTURAL COMBINATIONS OF LIGHTING DEVICES WITH OTHER ARTICLES, NOT OTHERWISE PROVIDED FOR
- F21V33/00—Structural combinations of lighting devices with other articles, not otherwise provided for
- F21V33/0064—Health, life-saving or fire-fighting equipment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0654—Lamps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
- A61N2005/066—Radiation therapy using light characterised by the wavelength of light used infrared far infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F21—LIGHTING
- F21Y—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES F21K, F21L, F21S and F21V, RELATING TO THE FORM OR THE KIND OF THE LIGHT SOURCES OR OF THE COLOUR OF THE LIGHT EMITTED
- F21Y2115/00—Light-generating elements of semiconductor light sources
- F21Y2115/10—Light-emitting diodes [LED]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Non-Portable Lighting Devices Or Systems Thereof (AREA)
Abstract
This invention discloses the dedicated light source and lamp for diabetic
retinopathy, where the light source comprises of substrate, green-yellow light-emitting
diodes and far-red light-emitting diodes devices. Both of the light-emitting diodes
devices are arranged on the substrate mentioned above. The lamp comprises of
control power supply and lampshade, where the former is to supply power to green
yellow light-emitting diodes and far-red light-emitting diodes devices while the latter
covers the substrate, green-yellow light-emitting diodes and far-red light-emitting
diodes devices internally. Merit of this invention: A dedicated lamp source that can be
used for household lighting, and diabetic retinopathy preventing and therapy of
patients with diabetes.
1/4
Figures of the Specification
Fig. 1
Screwed Constant-current Cooler Light source Lampshade
nipple drive
Fig. 2
Fig. 3
Description
1/4
Figures of the Specification
Fig. 1
Screwed Constant-current Cooler Light source Lampshade nipple drive
Fig. 2
Fig. 3
Dedicated Light Source and Lamp for Diabetic Retinopathy
Technical Field
This invention falls into the healthy lighting field, and more specifically, refers to
the dedicated light source and lamp for diabetes with diabetic retinopathy.
Background
As one of the top four factors that result in blind for people, diabetic retinopathy is
one of the significant diabetes complications and accompanied with symptoms such
as hard exudation, bleeding spot, cotton-wool spot and macular edema. It may lead to
impaired vision and even blindness of patients with diabetes, thereby affecting the
patients'visual performance and quality of life seriously.
Diabetic retinopathy is related to the retinal hypoxia of diabetes in the dark
environment. Once the retinal blood flow of the patients with diabetes is impaired, the
retinal hypoxia will be further aggravated in the dark environment. So, the diabetic
retinopathy can be alleviated by preventing the dark adaptation of eyes at night, or in
particular, reducing the dark current of rod-shaped photoreceptor.
The effectiveness of treating diabetic retinopathy with far-red light
phototiomodulation (PBM) has been gradually verified in the animal experiments and
clinical care. The understanding of its action mechanism has also been deepened
along with the more profound researches. The mitochondrion is the place where cell
respiration produces energy. ATP (adenosine triphosphate), as the fuel of cell energy,
serves as the most direct energy source for living organism. Both of far-red light and
near-infrared light can activate the mammalian cell mitochondria to release a series of
signals, to improve the functional activity of mitochondria effectively.
The low-intensity laser or LED with a wavelength of 670 nm and 780 nm were mainly used as the light source of PBM for diabetic retinopathy.
Due to the strong coherence, the emission of laser has very narrow band
spectrum; and the emission of LED chips also has narrow band spectrum. However,
the absorption spectrum of cells has broad-band configuration and even becomes
wider after cell irradiation. According to the research on the synthesis rate of DNA and
RNA at cellular level, the spectrum that has bio-active effect on cells should also be
broad-band. So, it is recommended to use broad-band spectrum light source for
diabetic retinopathy photobiomodulation by using far-red light. However, the far-red
light source with broad-band spectrum is not adopted according to the existing
techniques.
Summary
This invention is to solve the technical problem of offering a dedicated light
source and lamp that can be used for both household lighting and diabetic retinopathy
prevention and treatment of patients with diabetes.
This invention solves the technical problems above through the following
technical means: The dedicated light sources that apply to diabetic retinopathy
include: Substrate, green-yellow LED devices and far-red LED devices. The two LED
devices above are arranged on the substrate mentioned above. The light source
integrates the green-yellow LED devices and far-red LED device, where, the former
can reduce the adaptation of patients with diabetes in a dark environment, while the
latter can restrain and repair the retina impairment, which not only satisfies the
household lighting of patients with diabetes, but also realizes photobiomodulation to
diabetic retinopathy through the far-red light.
Preferably, the substrate refers to one type or combination of plane structure,
curved structure and abnormal structure.
Preferably, the green-yellow LED devices has an emission wavelength of 457
nm-720 nm and a peak emission wavelength of 555 nm; the far-red LED devices has
an emission wavelength of 590-900 nm and a peak emission wavelength of 760 nm.
Being free from blue light, the green-yellow light with an emission wavelength of 457
nm-720 nm can eliminate the impairment and apoptosis of retinal cells and optic nerve
cells ascribed to the blue light, and reduce the hazards of LED light source to the
diabetic retinopathy. The peak emission wavelength 555 nm of green-yellow light is
consistent with the photopic vision peak of human eyes, and the wavelength at
high-energy side of green-yellow light is not lower than the high-energy side of
photopic vision response curve, to ensure the human eyes' maximum response
sensitivity to the light source developed in this invention. With a broad-band spectrum,
the far-red LED devices can better cover the absorption spectrum range of cells and
promote the diabetic retinopathy photobiomodulation. The far-red LED devices have a
peak emission wavelength of 760 nm, which is consistent with the 760 nm peak
absorption wavelength of human cell.
Preferably, the green-yellow LED devices and far-red LED devices are
respectively used and alternatively arranged on the substrate above. The
green-yellow LED devices and far-red LED devices are alternatively arranged on the
substrate above at different proportions, to generate different irradiances and satisfy
the requirements of human eyes for illuminating brightness of visible light.
This invention also provides a dedicated lamp that applies to the diabetic
retinopathy above and comprises control power supply and lampshade, where the
former is to supply power to the green-yellow LED devices and far-red LED devices
while the latter covers the substrate, green-yellow LED devices and far-red LED
devices internally.
Preferably, the manufacturing process of far-red LED devices includes:
Weigh and take far-red phosphor, and transparent silicone A and B at a mass
ratio of 1:1. The far-red phosphor accounts for 10%-90% of total weight of transparent
silicone A and B;
Perform vacuum mixing and defoaming to far-red phosphor, transparent silicone
A and B by using the vacuum defoaming machine to get the evenly mixed powder
glue;
Fix the LED chip onto the LED holder and weld the anode and cathode on the
LED holder; titrate the evenly mixed powder glue onto the LED chip by using the glue
dispenser;
Move the LED holder and LED chip into the vacuum oven and perform
solidification for 1-6 h at vacuum conditions at 150°C to get the far-red LED devices.
Preferably, the manufacturing process of green-yellow LED devices includes:
Weigh and take green-yellow phosphor and transparent silicone A and B at the
mass ratio of 1:1. The green-yellow phosphor accounts for 10%-90% of total weight of
transparent silicone A and B;
Perform vacuum mixing and defoaming to green-yellow phosphor and
transparent silicone A and B by using the vacuum defoaming machine to get the
evenly mixed powder glue;
Fix the LED chip onto the LED holder and weld the anode and cathode on the
LED holder; titrate the evenly mixed powder glue onto the LED chip by using the glue
dispenser;
Move the LED holder and LED chip into the vacuum oven and perform
solidification for 1-6 h at vacuum conditions at 150 °C to get the green-yellow LED
devices.
Preferably, the far-red phosphors above includes one type or combination
of Y[(A 75 Sc 25 )0.92Cro0 8 1O , Y(AlO 9 6CrO4),(BO3 )4, (MgO. 97 Cr0),Nb2098 and
Li( ScO.96Cro.04 )S2 06
. Preferably, the synthesis process of Y [(A 7 5 Sc) 0 .92 CrO0 8 ] 12 above includes:
Take Y20 3 , Sc20 3 , Al203 and Cr(NO3 ) 9H20 as raw materials; weigh and take raw
materials according to the chemical formula of Y [(Al 75 ScO2 5 0) 9 2 Cr 0 8 012, add the
BaF2 and H 3B03 , which account for 2.5% and 2% of total mass or raw materials
respectively, as the flux; mix the raw materials and flux above evenly and put the
grinded products into the alundum crucible for high-temperature calcinations for 6 h at
1,500 °C°C; make sure to conduct high-temperature calcinations in chamber furnace
at the ambient environment; grind and wash the discharged products repeatedly to
get Y[(Al 75 ScO 25 )0 .92 Cro 8 ] 12
Preferably, the synthesis process ofY(A 0 . 96CrO4) 3 (BO3 ) 4 above includes: Use
Al20 3 H3B0 3 and Cr(NO3) 39H20 as raw materials; weigh and take the raw
materials according to the chemical formula of (A -96 r0 4 )3 (BO3 ) 4 grind them fully
and then put them into the alundum crucible, fire them for 2 h at 500 °C in the ambient
environment; take out and grind them, apply secondary calcining for 4 h at 1,250 °C;
grind and wash the discharged products repeatedly to getY(A 0 96CrO) (BO3 )4
Preferably, the preparation process of (MgO 0 3), Nb20, 9 7 Cr. above includes: Use
MgO , Nb 2 05 and Cr(NO3 ) 9H20 as raw materials; weigh and take the raw
materials according to the chemical formula of (MgO.9 7 CrO 03 )4 Nb2 Og, add the NH4 Cl, which accounts for 2% of total mass of raw material, as the flux; mix the raw materials and flux above evenly, put the evenly mixed raw materials and flux into the alundum crucible for presintering for 2 h at 500 °C; apply secondary calcining for 4 h at
1,250 °C; grind and wash the discharged products repeatedly to get
(Mg0 9 7Cr.03 ),Nb20s-9 .
Preferably, the preparation process of Li(ScO 9 6 CrO04)Si 2 0 6 includes: Use Li2 CO3
, Sc20 3, SiO2 and Cr(NO3) 9H20 as raw materials; weigh and take the raw materials
according to the chemical formula of Li(ScO9 6 Cr0 4 )Si206; grind the raw materials and
put them into the alundum crucible for presintering for 2 h at 500 °C; apply secondary
calcining for 8h at 1,100°C; grind and wash the discharged products repeatedly to get
(Mg0 9 7Cr.03 ) Nb20s-9 .
Preferably, the [(YOGdOI) 09 Ceo.02 3 A5012 is used as green-yellow phosphor
above.
Preferably, the preparation process of [(YOGdO 1 )0 9 , Ceo 0 3A5012 includes: Use
Y20 3 , Gd203 , A1 2 0 3 and CeO2 as the raw materials; weigh and take the raw
materials according to the chemical formula of [(YOGdO. 1 0) 8 Ceo.02 3A50 12 ; add the
BaF2 and H 3B03 , which account for 2.5% and 2% of total mass or raw materials
respectively, as the flux; mix the raw materials and fluxes above evenly and put the
grinded products into the alundum crucible for high-temperature calcinations for 6 h at
1,500 °C; make sure to conduct high-temperature calcinations in tube furnace at the
%H2+75%N2 reducing atmosphere; grind and wash the discharged products
repeatedly to get green-yellow phosphor.
Merits of this invention:
(1) This invention is about a dedicated light source which applies to diabetic
retinopathy and integrates the green-yellow light and far-red light, where, the former
can reduce the adaptation of patients with diabetes in a dark environment, while the
latter can restrain and repair the retina impairment, which not only satisfies the
household lighting of patients with diabetes, but also realizes photobiomodulation
therapy to diabetic retinopathy through the far-red light.
(2) Being free from blue light, the green-yellow light in this invention can
eliminate the impairment and apoptosis, ascribed to the blue light, of retinal cells and
optic nerve cells and reduce the hazards of LED light source to the diabetic
retinopathy.
(3) The peak emission wavelength of green-yellow light in this invention is
consistent with the photopic vision peak of human eyes, the low-energy side of
green-yellow light emission spectrum is not higher than photopic vision response
curve, and the wavelength at high-energy side of green-yellow light is not lower than
the high-energy side of photopic vision response curve, to ensure the human eyes'
maximum response sensitivity to the light source developed in this invention.
(4) With a broad band spectrum, the far-red LED devices in this invention can
better cover the absorption spectrum range of cells; it not only covers the absorption
spectrum before cell stimulation, but also designs the ratio of far-red light fluorescent
powder, to ensure that emission spectrum of far-red LED devices reaches the broad
band spectrum after cell stimulation. The far-red LED devices with broad band
spectrum can better promote the diabetic retinopathy photobiomodulation.
Brief Description of the Figures
Fig. 1 is the schematic diagram for dedicated light source of diabetic retinopathy
and light source of LED bulb which are disclosed in Example 1 of this invention;
Fig. 2 is the schematic diagram for dedicated light source of diabetic retinopathy
and LED bulb which are disclosed in Example 1 of this invention;
Fig. 3 is the schematic diagram for dedicated light source of diabetic retinopathy
and light source of lamp in detailed implementation method which are disclosed in
Example 1 of this invention;
Fig .4 is the schematic diagram for dedicated light source of diabetic retinopathy
and spotlight of lamp;
Fig. 5 is the schematic diagram for dedicated light source of diabetic retinopathy
and downlight of lamp which are disclosed in Example 1 of this invention;
Fig. 6 is the schematic diagram for dedicated light source of diabetic retinopathy
and strip light source in lamps which are disclosed in Example 1 of this invention;
Fig. 7 is the schematic diagram for dedicated light source of diabetic retinopathy
and the light source made of strip light source structure in lamp which are disclosed in
Example 1 of this invention;
Fig. 8 is the schematic diagram for dedicated light source of diabetic retinopathy
and table lamp made of strip light source in lamp which are disclosed in Example 1 of
this invention;
Fig. 9 is the schematic diagram for dedicated light source of diabetic retinopathy
and circular light source in lamp which are disclosed in Example 1 of this invention;
Fig. 10 is the schematic diagram for dedicated light source of diabetic retinopathy
and table lamp made of circular light source which are disclosed in Example 1 of this
invention;
Fig. 11 is the schematic diagram for dedicated light source of diabetic retinopathy
and light source made of green-yellow light strip and far-red light strip of lamp which
are disclosed in Example 1 of this invention;
Fig. 12 is the schematic diagram for dedicated light source of diabetic retinopathy
and panel light made of green-yellow light strip and far-red light strip of lamp which are
disclosed in Example 1 of this invention;
Fig. 13 is the schematic diagram for dedicated light source of diabetic retinopathy
and floor lamp made of light source of bulb light or circular light source in lamp which
is disclosed in Example 1 of this invention.
Description of the Invention
The technical plan in this invention's example will be described clearly and
completely combining the invention example, in order to highlight the purpose,
technical plan and merits of this invention's example. Obviously, the examples
described are some examples of this invention instead of all. On the basis of the
examples in this invention, all other examples acquired by the general technicians in
this field without making innovations belong to the protection scope of this invention.
Example 1
The dedicated light sources applied to diabetic retinopathy include: Substrate,
green-yellow LED devices and far-red LED devices, where the former has an
emission wavelength of 457 nm-720 nm and a peak emission wavelength of 555 nm
and the latter has an emission wavelength of 590-900 nm and a peak emission
wavelength of 760 nm.
The green-yellow LED devices and far-red LED devices, both of which are
arranged on the substrate mentioned above. The substrate refers to one type or
combination of plane structure, curved structure and abnormal structure, where the
curved structure can be hemisphere, ellipsoid or ball structure; the abnormal structure
can be surface wave and surface flange type. The substrate is used for fixing the
green-yellow LED devices and far-red LED devices; select the green-yellow LED devices and far-red LED devices with different particles to form different light sources, apply the light sources of different shapes to the corresponding lampshades, and produce the bulb lights, spotlights, down lights, straight fluorescent lights, mirror lights, table lamps, panel lights and floor lamps which conform to the market requirements.
This invention also provides a dedicated lamp that applies to the diabetic
retinopathy above and comprises control power supply and lampshade, where the
former is to supply power to the green-yellow LED devices and far-red LED devices
while the latter covers the substrate, green-yellow light led and far-red LED devices
internally.
Fig. 1 is the schematic diagram for light source that is composed of bulb light by
fixing the LED devices onto the circular ceramic substrate. In this figure, the
green-yellow LED devices and far-red LED devices are arranged alternatively; the
blocks filled in black represent the far-red LED devices, while the unfilled blocks
represent the green-yellow LED devices. The far-red LED devices are fewer than the
green-yellow LED devices. This figure shows 8 far-red LED devices and 14
green-yellow LED devices. Fig. 2 is the schematic diagram for bulb light composed of
light sources by using the bulb lights shown in Fig. 1. The basic structure of blub light
includes E24 standard thread structure, constant-current drive, light source and
lampshade. The lamps are installed based on the existing methods. No further
description is made to lamp assembly and position relationship of lamps, for the lamp
assembly is not the invention's improvement point.
In actual applications, the individual drive circuit can be used for controlling the
green-yellow LED devices and far-red LED devices. The green-yellow LED devices
keep running when driven by the constant-flow drive; the drive power of far-red LED
devices, which is connected to the timer, can be interrupted after running for 5-50 min and then start work again. It is running based on pulse drive. The power of light source is set as 3-18 W. The area of far-red light accounts for 5-50 % of total spectrum area, where the area of far-red light is formed by the spectrum within the wavelength of 590-900 nm, while the area of green-yellow light is formed by the spectrum within the wavelength of 457 nm-720 nm. The green-yellow LED devices has the irradiance up to 15-500 Lux/m 2 to satisfy the requirements for illuminating brightness of human eyes. It can adjust the quantity ratio between far-red LED devices and green-yellow
LED devices, as well as irradiance of green-yellow light, spectral components of
far-red light and power of light source.
As shown in Fig. 3, the green-yellow LED devices and far-red LED devices of
different particles are arranged. The green-yellow LED devices has 6 particles, while
the far-red LED devices has 4. The LED devices are fixed on the circular ceramic or
PCB substrate to form the light source. The spotlight and down light respectively
shown in Fig. 4 and 5 are prepared by using this light source. The selection of LED
devices, quality requirements of light source and lamp drive control are the same with
bulb lights in Fig. 2. The lamp brightness can be adjusted continuously, in order to
better satisfy the requirements for perception brightness of human eyes at different
space-time environments. Both of the down light and spotlight can shine and project it
to the partial area of patients with diabetes; for example, the pillow coverage area
when patients with diabetes are sleeping at night.
As shown in Fig. 6, the green-yellow LED devices and far-red LED devices of
different particles are arranged. The LED devices are fixed on the strip ceramic or
PCB substrate to form the light source. The T5/T8 fluorescent lamp, bedside lamp and
mirror light source shown in Fig. 7 are prepared by using this light source. The
selection of LED devices, quality requirements of light source and lamp drive control are the same with bulb lights in Fig. 2. The lamp brightness can be adjusted continuously, in order to better satisfy the requirements for perception brightness of human eyes at different space-time environments. For patients with diabetes, the bedside lamp can be kept on at night to reduce the depolarization of outer rod cells of retina.
As shown in Fig. 9, the green-yellow LED devices and far-red LED devices of
different particles are arranged. The LED devices are fixed on the circular ceramic or
PCB substrate to form the circular light source. The desk lamp shown in Fig. 10 is
prepared by using this light source. The selection of LED devices, quality
requirements of light source and lamp drive control are the same with bulb lights in Fig.
2. The lamp brightness can be adjusted continuously, in order to better satisfy the
requirements for perception brightness of human eyes at different space-time
environments. The desk lamp applies to reading, working or partial lighting of patients
with diabetes.
As shown in Fig. 11, select the green-yellow LED devices and far-red LED
devices, where the former is fixed on the PCB substrate as green-yellow light strip,
while the latter is fixed on the PCB substrate as the far-red light strip. Fix the
green-yellow light strip and far-red light strip at the surroundings of panel light
respectively. For two sides which are in parallel, the light strips can be fixed at one
side or both sides depending on the lighting efficiency, power and quantity of beads.
Fig. 12 is the schematic diagram of fixing the same LED devices on two parallel lines
or fixing different LED devices at the relative side. The panel light shown in Fig. 12 is
prepared by using the light source structure in Fig. 11. The selection of LED devices,
quality requirements of light source and lamp drive control are the same with bulb
lights in Fig. 2. The lamp switch and brightness can be adjusted continuously, in order to better satisfy the requirements for perception brightness of human eyes at different space-time environments. The panel light in bedroom of patients with diabetes will be kept on at night, in order to reduce the depolarization of outer rod cells of retina.
As shown in Fig. 13, the floor lamp is prepared by using the light source of bulb
light in Fig. 1 or circular light source in Fig. 3. This floor lamp applies to household
lighting, reading and nighttime lighting of patients with diabetes; and, with the help of
reflector lamp cup, it can project the light to the face of patients with diabetes. The
selection of LED devices, quality requirements of light source and lamp drive control
are the same with bulb lights in Fig. 2. The lamp brightness can be adjusted
continuously, in order to better satisfy the requirements for perception brightness of
human eyes at different space-time environments.
On basis of the technical scheme above, the example 1 of this invention has the
following work process and principle: The light source integrates the green-yellow
LED devices and far-red LED devices, where, the former can reduce the adaptation of
patients with diabetes in a dark environment, while the latter can restrain and repair
the retina impairment, which not only satisfies the household lighting of patients with
diabetes, but also realizes photobiomodulation therapy to diabetic retinopathy through
the far-red light. Being free from blue light, the green-yellow light with an emission
wavelength of 457 nm-720 nm can eliminate the impairment and apoptosis, ascribed
to the blue light, of retinal cells and optic nerve cells and reduce the hazards of LED
light source to the diabetic retinopathy. The peak emission wavelength 555 nm of
green-yellow light is consistent with the photopic vision peak of human eyes, and the
wavelength at high-energy side of green-yellow light is not higher than the
high-energy side of photopic vision response curve, to ensure the human eyes'
maximum response sensitivity to the light source developed in this invention. With a broad band spectrum, the far-red LED devices can better cover the absorption spectrum range of cells and promote the photobiomodulation treatment to diabetic retinopathy The far-red LED devices has a peak emission wavelength of 760 nm, which is consistent with the 760 nm peak absorption wavelength of human cell.
Example 2
In the example 2 of this invention, the green-yellow LED devices and far-red LED
devices are respectively used and alternatively arranged on the substrate above. The
substrate above is used for fixing and supporting LED devices, cooling and heat
conduction, as well as alternative arrangement of green-yellow LED devices and
far-red LED devices. The green-yellow LED devices and far-red LED devices are
alternatively arranged on the substrate above at different proportions, to generate
different irradiances and satisfy the requirements of human eyes for illuminating
brightness of visible light.
Wherein, the manufacturing process of far-red LED devices includes:
Weigh and take far-red phosphors, and transparent silicone A and B at a mass
ratio of 1:1. The far-red phosphors accounts for 10%-90% of total weight of
transparent silicone A and B. The transparent silicone A and B, which are modeled
Y550A and Y500B respectively, are made by Jiangxi Leader Technology Co., Ltd.
Perform vacuum mixing and defoaming to far-red phosphor, transparent silicone
A and B by using the Marath MT-1000 vacuum defoaming machine to get the evenly
mixed powders glue;
Fix the LED chip onto the LED holder and weld the anode and cathode on the
LED holder; titrate the evenly mixed powders glue onto the LED chip by using
Shenzhen Axis Auto-control D-260 dispenser;
Move the LED holder and LED chip into the vacuum oven and perform solidification for 1-6 h at vacuum conditions at 150 °C to get the far-red LED devices; when it is on, measure the emission spectrum of LED devices by using the Ocean
Optics USB4000 fiber optic spectrometer; wherein, the vacuum oven is modeled
DZF-6020 of Shanghai Boxun. The LED holder and LED chip are semi-finished
products and high-power LED chips modeled 5730 of APT Electronics Co., Ltd. after
crystal fixing and wire welding.
The preparation process of Y[(Al,7 5 Sco. 25 )0 .92 Cro 08 12 above includes: Take
Y20 3 , Sc20 3 , A1 2 03 and Cr(NO3 ) 9H20 as raw materials; weigh and take raw
materials according to the chemical formula of 3Y[( Al 75 Sco. 2 5 ) 0 .92 Cro 8 012 , add the
BaF2 and H 3B03 , which account for 2.5% and 2% of total mass or raw materials
respectively, as the flux; mix the raw materials and fluxes above evenly, grind them for
min by using the high-energy vibrating ball mill and put the grinded products into
the alundum crucible for high-temperature calcinations for 6 h at 1,500 C; increase
the temperature to 600 °C at a speed of 10 °C/ min and apply thermal insulation for 30
min; increase the temperature to 900 °C at a speed of 5 °C/ min and apply thermal
insulation for 60 min; increase the temperature to 1,200 °C at a speed of 5 °C/ min and
apply thermal insulation for 60 min; increase the temperature to 1,500 °C at a speed of
4 °C/ min and apply thermal insulation for 480 min; decrease the temperature to
900 °C at a speed of 5 °C/ min and apply thermal insulation for 60 min. Finally, the
temperature decreases to 600 °C at a speed of 5 °C/min and cut off power supply.
Make sure to conduct high-temperature calcinations in chamber furnace at the
ambient environment; grind and wash the discharged products repeatedly to get
Y 3 [(A10 7 5Sc.025 ) .902 Cro5 01 wherein, washing is made to remove the unreacted flux;
remove the absorbed debris on the surface of phosphor particles to keep it clean, improve the absorption efficiency and luminous efficiency and reduce the scattering.
Please be noticed, the green-yellow phosphors and far-red phosphors sold on
market can be used in this invention and it is unlimited to the ones provided in this
invention, which is to provide the lamps with green-yellow LED devices and far-red
LED devices, in order to satisfy household lighting of patients with diabetes and
realize diabetic retinopathy prevention and treatment.
On the basis of technical scheme above, the specific lamp provided in this
invention applies to diabetic retinopathy and also integrates the household lighting
and diabetic retinopathy prevention and treatment of patients with diabetes. By
integrating the far-red LED devices into the lamps, it can provide far-red light to light
source to perform photobiomodulation to retina of patients with diabetes, in order to
improve the activity of mitochondria and cell metabolism, promote the blood flow of
tissue, motivate the growth of nerve and cynapse, restrain the generation of
superoxide induced by diabetes, restrain the leukocytostasis and expression of ICAM
ICM-1, reserve the expression of MnSOD, reduce the inflammation induced by
diabetes and vascular anomaly of retina; restrain the premature failure of diabetic
retinopathy and provide active treatment to the diabetic retinopathy. Meanwhile, the
green-yellow LED devices can minimize the dark adaptation of human eyes and
reduce the damages of retina due to anoxia of patients with diabetes in a dark
environment. Besides, the peak emission spectrum of lamp is consistent with the
peak photopic vision response of human eyes, and low-energy side of emission
spectrum is not lower than the photopic vision response curve, to ensure the human
eyes' maximum response sensitivity to the light sources.
In actual application, one type or combination of Y Al, 75 Sco. 25 )0 9. 2 Cro 012
Y(Al 0 9 6CrO 4 ),(BO3 )4 (Mg 0 9 7Cr. 0 3) 4Nb208-98 and Li(ScO 9CrO 6 2 06 can be mixed to 40)Si get the far-red phosphor.
The examples above are to introduce the technological schemes of this invention,
instead of setting limitations; even if the invention is introduced in details by referring
to the examples above, the general technicians in this field should understand the
followings: It is allowed to modify the technical schemes in the examples above, or
replace the technical characteristics; however, such modifications or replacements
should not make the technical scheme separated from the idea and scope of technical
schemes in the examples.
Claims (10)
1. Feature of the dedicated light source applied to diabetic retinopathy: The light
source comprises of substrate, green-yellow LED devices and far-red LED devices; to
be specific, both of green-yellow LED devices and far-red LED devices are arranged
on the substrate mentioned above.
2. Feature of the dedicated light source applied to diabetic retinopathy as
mentioned in Claim 1: The substrate refers to one type or combination of plane
structure, curved structure and abnormal structure.
3. Feature of the dedicated light source applied to diabetic retinopathy as
mentioned in Claim 1: The green-yellow LED devices have an emission wavelength of
457 -720 nm and a peak emission wavelength of 555 nm; the far-red LED devices
have an emission wavelength of 590-900 nm and a peak emission wavelength of 760
nm.
4. Feature of the dedicated light source applied to diabetic retinopathy as
mentioned in Claim 1: The green-yellow LED devices and far-red LED devices are
respectively used and alternatively arranged on the substrate above.
5. Feature of the dedicated light source applied to diabetic retinopathy as
mentioned in Claim 1-4: The lamp comprises of: Control power supply and lampshade,
wherein,
The power supply is to supply power to green-yellow LED devices and far-red
LED devices;
The lampshade covers the substrate, green-yellow LED devices and far-red LED
devices internally.
6. Feature of the dedicated light source applied to diabetic retinopathy as
mentioned in Claim 5: The manufacturing process of far-red LED devices includes:
Weigh and take far-red phosphors, and transparent silicone A and B at a mass
ratio of 1:1. The far-red phosphors account for 10%-90% of the total weight of
transparent silicone A and B;
Perform vacuum mixing and defoaming to far-red phosphors, and transparent
silicone A and B by using the vacuum defoaming machine to get the evenly mixed
powder glue;
Fix the LED chip onto the LED holder and weld the anode and cathode on the
LED holder; titrate the evenly mixed powder glue onto the LED chip by using the glue
dispenser;
Move the LED holder and LED chip into the vacuum oven and perform
solidification for 1-6 h at vacuum conditions at 150 °C to get the far-red LED devices.
7. Feature of the dedicated light source applied to diabetic retinopathy as
mentioned in Claim 5: The manufacturing process of green-yellow LED devices
includes:
Weigh and take green-yellow phosphor and transparent silicone A and B at the
mass ratio of 1:1. The green-yellow phosphor accounts for 10%-90% of the total
weight of transparent silicone A and B;
Perform vacuum mixing and defoaming to green-yellow phosphor and
transparent silicone A and B by using the vacuum defoaming machine to get the
evenly mixed powder glue;
Fix the LED chip onto the LED holder and weld the anode and cathode on the
LED holder; titrate the evenly mixed powder glue onto the LED chip by using the glue
dispenser;
Move the LED holder and LED chip into the vacuum oven and perform
solidification for 1-6 h at vacuum conditions at 150 °C to get the green-yellow LED devices.
8. Feature of the dedicated light source applied to diabetic retinopathy as
mentioned in Claim 6: The far-red phosphors above includes one type or combination
5 0 2 5) 0.92 Cro 0 8 ] 12 of Y[(AO 7 sc Y(AlO 9 6CrO 4 ),(BO3) 4, (MgO 97Cr.03 )4 Nb 2O898 and
Li( ScO.96 Cro.04 )S2 06 .
The preparation process of Y [(A. 75 Sc) 0 .92 Cro 0 12 above includes: Take
Y20 3 , Sc20 3 , A1 2 03 and Cr(NO3) 9H20 as raw materials; weigh and take raw
materials according to the chemical formula of Y[(A 7 5 ScO2 5 )0 .92 cro08 012, add the
BaF2 and H 3B03 , which account for 2.5% and 2% of the total mass or raw
materials respectively, as the flux; mix the raw materials and fluxes above evenly and
put the grinded products into the alundum crucible for high-temperature calcinations
for 6h at 1,500 C; make sure to conduct high-temperature calcinations in chamber
furnace at the ambient environment; grind and wash the discharged products
repeatedly to get Y[( A10 75 ScO25 )0.92 1 Cro0 8 12
The preparation process of 96 ro)(BO3 ) 4 above includes: UseA1 2 0
H 3B0 3 and Cr(NO3 );9H 20 as raw materials; weigh and take the raw materials
according to the chemical formula ofY(A -96C 04 )(BO 3 ) 4 , grind them fully and then
put them into the alundum crucible, fire them for 2 h at 500 °C in the ambient
environment; take out and grind them, apply secondary calcining for 4 h at 1,250 C;
grind and wash the discharged products repeatedly to get °-96CrO.4)X (BO3)
The preparation process of (MgO9 7 Cr 03)4Nb20,s above includes: Use MgO,
Nb20 5 and Cr(NO3) 9H20 as raw materials; weigh and take the raw materials
according to the chemical formula of (MgO9 7 Cr.03),Nb208'9, add the NH4Cl, which
accounts for 2% of total mass of raw material, as the flux; mix the raw materials and
fluxes above evenly, put the evenly mixed raw materials and fluxes into the alundum
crucible for presintering for 2 h at 500 C; apply secondary calcining for 4 h at
1,250 °C; grind and wash the discharged products repeatedly to get
(Mg0 9 7Cr.03 ) Nb20s-9 .
The preparation process of Li(ScO9 6 CrO4)Si206 includes: Use Li2 CO3 , Sc203,
SiO2 and Cr(NO3 ) 9H20 as raw materials; weigh and take the raw materials
according to the chemical formula of Li(ScO9 6 Cr0 4 )Si206; grind the raw materials and
put them into the alundum crucible for presintering for 2 h at 500 C; apply secondary
calcining for 8 h at 1,100 C; grind and wash the discharged products repeatedly to
get (MgO97 CrO 03 ),Nb20s 8 98 .
9. Feature of the dedicated light source applied to diabetic retinopathy as
mentioned in Claim 7: The [(YOGdO. 1 )09 Ceo 02 3A1 50 1 2 is used as green-yellow
phosphorabove.
10. Feature of the dedicated light source applied to diabetic retinopathy as
mentioned in Claim 9: The preparation process of [(YOGdO.1 )09 CeO02 A1 5 0 12
includes: Use Y203, Gd20 3 , A20 and CeO2 as the raw materials; weigh and take
the raw materials according to the chemical formula of [(YOGdO) 8 Ce02 A50 12 ;
add the BaF2 and H 3B0 3 , which account for 2.5% and 2% of total mass or raw
materials respectively, as the fluxes; mix the raw materials and fluxes above evenly and put the grinded products into the alundum crucible for high-temperature calcinations for 6 h at 1,500 °C; make sure to conduct high-temperature calcinations in tube furnace at the 25%H2+75%N2 reducing atmosphere; grind and wash the discharged products repeatedly to get green-yellow phosphor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021101739A AU2021101739A4 (en) | 2021-04-06 | 2021-04-06 | Dedicated Light Source and Lamp for Diabetic Retinopathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021101739A AU2021101739A4 (en) | 2021-04-06 | 2021-04-06 | Dedicated Light Source and Lamp for Diabetic Retinopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021101739A4 true AU2021101739A4 (en) | 2021-05-20 |
Family
ID=75911183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021101739A Active AU2021101739A4 (en) | 2021-04-06 | 2021-04-06 | Dedicated Light Source and Lamp for Diabetic Retinopathy |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2021101739A4 (en) |
-
2021
- 2021-04-06 AU AU2021101739A patent/AU2021101739A4/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Behar-Cohen et al. | Light-emitting diodes (LED) for domestic lighting: any risks for the eye? | |
| WO2021035782A1 (en) | Special light source and light fixture suitable for diabetic retinopathy | |
| KR101986700B1 (en) | Lighting systems for protecting circadian neuroendocrine function | |
| US7614763B2 (en) | Operating table lamp | |
| CN101238326B (en) | Operating lumina | |
| CN209782327U (en) | Eye-protecting lamp convenient to adjust light-emitting angle and capable of reducing blue light damage | |
| JPWO2003019072A1 (en) | LED light with adjustable color temperature | |
| CN102573228B (en) | Healthy LED (light-emitting diode) illuminating lamp | |
| CN102352970A (en) | Novel LED (light emitting diode) light source and illumination device thereof | |
| CN105870304A (en) | LED light source with adjustable wavelength | |
| JP2009117160A (en) | Led lighting system | |
| EP1285676B1 (en) | Light source for modulation of circadian rhythms | |
| CN109000160A (en) | A kind of quasi- natural light LED light source and lighting device | |
| AU2021101739A4 (en) | Dedicated Light Source and Lamp for Diabetic Retinopathy | |
| CN109027720A (en) | A kind of optimization method of LED light source | |
| WO1989008476A1 (en) | Portable light dosage system | |
| CN103225768B (en) | A kind of blue light prevention desk lamp | |
| CN203421521U (en) | LED plant light supplement lamp | |
| CN203273471U (en) | Blue-light-resistant table lamp | |
| CN113041505A (en) | Using method of lamp group for treating myopia | |
| CN202876114U (en) | Multichip module LED irradiation therapeutic device capable of adjusting size of light spot in self-adaptive manner | |
| CN104100878A (en) | Secondary reflection type LED (light-emitting diode) shadowless lamp for operation | |
| CN112420902A (en) | Light source module and lighting device comprising same | |
| JP2003325684A (en) | Light beam treating device | |
| CN110630927A (en) | LED eye-protecting desk lamp with sleep improving function and method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) |